Skip to Main Content (Press Enter)

Logo UNIMORE
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNIMORE

|

UNI-FIND

unimore.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Articolo
Data di Pubblicazione:
2022
Citazione:
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer / Geyer, C. E.; Garber, J. E.; Gelber, R. D.; Yothers, G.; Taboada, M.; Ross, L.; Rastogi, P.; Cui, K.; Arahmani, A.; Aktan, G.; Armstrong, A. C.; Arnedos, M.; Balmana, J.; Bergh, J.; Bliss, J.; Delaloge, S.; Domchek, S. M.; Eisen, A.; Elsafy, F.; Fein, L. E.; Fielding, A.; Ford, J. M.; Friedman, S.; Gelmon, K. A.; Gianni, L.; Gnant, M.; Hollingsworth, S. J.; Im, S. -A.; Jager, A.; Johannsson, O. Th.; Lakhani, S. R.; Janni, W.; Linderholm, B.; Liu, T. -W.; Loman, N.; Korde, L.; Loibl, S.; Lucas, P. C.; Marme, F.; Martinez De Duenas, E.; Mcconnell, R.; Phillips, K. -A.; Piccart, M.; Rossi, G.; Schmutzler, R.; Senkus, E.; Shao, Z.; Sharma, P.; Singer, C. F.; Spanic, T.; Stickeler, E.; Toi, M.; Traina, T. A.; Viale, G.; Zoppoli, G.; Park, Y. H.; Yerushalmi, R.; Yang, H.; Pang, D.; Jung, K. H.; Mailliez, A.; Fan, Z.; Tennevet, I.; Zhang, J.; Nagy, T.; Sonke, G. S.; Sun, Q.; Parton, M.; Colleoni, M. A.; Schmidt, M.; Brufsky, A. M.; Razaq, W.; Kaufman, B.; Cameron, D.; Campbell, C.; Tutt, A. N. J.; Sevelda, P.; Haslbauer, F.; Penzinger, M.; Ohler, L.; Tinchon, C.; Greil, R.; Heibl, S.; Bartsch, R.; Wette, V.; Singer, C. F.; Pasterk, C.; Helfgott, R.; Pristauz-Telsnigg, G.; Stoger, H.; Weltermann, A.; Egle, D.; Thiel, I.; Fuchs, D.; Rumpold, H.; Strasser-Weippl, K.; Rautenberg, B.; Muller, V.; Schmidt, M.; Paepke, S.; Aydogdu, M.; Thomssen, C.; Rom, J.; Mau, C.; Fasching, P.; Gohring, U. -J.; Kuhn, T.; Noeding, S.; Kummel, S.; Hackmann, J.; Stickeler, E.; Joshi, A.; Dewar, J.; Friedlander, M.; Antill, Y.; Woodward, N.; Abdi, E.; Tiley, S.; George, M.; Boadle, D.; Goodwin, A.; Van Der Westhuizen, A.; Kannourakis, G.; Murray, N.; Mccarthy, N.; Kroep, J.; De Boer, M.; Heijns, J.; Erdkamp, F.; Bakker, S.; Sonke, G. S.; Sami, A.; Mackey, J.; Prady, C.; Eisen, A.; Desbiens, C.; Patocskai, E.; Ferrario, C.; Bordeleau, L.; Chalchal, H.; Niraula, S.; Ido, Wolf; Duhoux, F.; Randal, D'Hondt; Luce, S.; Roodenbeke, D. T. D.; Papadimitriou, K.; Borms, M.; Quaghebeur, C.; Jacot, W.; Brain, E.; Venat-Bouvet, L.; Lortholary, A.; Nowecki, Z.; Cardoso, F.; Hayward, R.; Bella, S.; Lazzaro, M. F.; Pilnik, N.; Fein, L. E.; Blajman, C.; Lerzo, G.; Varela, M.; Zarba, J. J.; Kaen, D.; Constanzo, M. V.; Tio, J.; Siggelkow, W.; Jackisch, C.; Grischke, E. M.; Zahm, D.; Tato-Varela, S.; Schmatloch, S.; Klare, P.; Stefek, A.; Rhiem, K.; Hoffmann, O.; Deryal, M.; Groll, I.; Ledwon, P.; Uleer, C.; Krabisch, P.; Potenberg, J.; Darsow, M.; Park-Simon, T. -W.; Hoffkes, H. -G.; Emde, T. -O.; Graffunder, G.; Tome, O.; Forstmeyer, D.; Terhaag, J.; Salat, C.; Kast, K.; Weniger, S.; Schreiber, C.; Heinrich, B.; Dieterich, M.; Wullner, M. P.; Conejero, R. A.; Garcia Saenz, J. A.; Martinez, L. C.; Lanza, A. A.; Murillo, S. M.; Carrasco, F. H.; Tormo, S. B.; Lopez, I. A.; Delgado Mingorance, J. I.; Gomez, E. A.; Santisteban, M.; Jurado, J. C.; Quiroga, V.; Borrego, M. R.; Martinez De Duenas, E.; Ales Martinez, J. E.; De La Haba, J.; Janez, N. M.; Lescure, A. R.; Torres, A. A.; Crusades, G. L.; Gonzalez-Santiago, S.; Aragones, A. M.; Ortega, A. L.; Molins, A. B.; Chacon Lopez-Muniz, J. I.; Jimenez, M. M.; Bertran, A. S.; Rodriguez, C.; Cortijo, L. G.; Cretella, E.; Cortesi, L.; Ruggeri, E. M.; Verusio, C.; Gori, S.; Bonetti, A.; Mosconi, A. M.; Johannsson, O.; Jerusalem, G.; Neven, P.; Nagy, T.; Pinotti, G.; Colleoni, M. A.; Bernardo, A.; Gianni, L.; Bucci, E.; Biganzoli, L.; Dedes, K.; Novak, U.; Zaman, K.; Braybrooke, J.; Winter, M.; Rea, D.; Kelleher, M.; Barrett, S.; Chan, S.; Hickish, T.; Hurwitz, J.; Conibear, J.; Jegannathen, A.; Parton, M.; Tutt, A.; Allerton, R.; Borley, A.; Armstrong, A.; Copson, E.; Levitt, N.; Abraham, J.; Perren, T.; Roylance, R.; Ishida, K.; Toyama, T.; Masuda, N.; Watanabe, J.; Tokunaga, E.; Kinoshita, T.; Rai, Y.; Takada, M.; Yanagita, Y.; Nakamura, R.; Nakayama, T.; Naoi, Y.; Iwata, H.
Abstract:
Background: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic variants in germline BRCA1 or BRCA2 (gBRCA1/2pv) and high-risk, human epidermal growth factor receptor 2-negative, early breast cancer (EBC). The first pre-specified interim analysis (IA) previously demonstrated statistically significant improvement in invasive disease-free survival (IDFS) and distant disease-free survival (DDFS). The olaparib group had fewer deaths than the placebo group, but the difference did not reach statistical significance for overall survival (OS). We now report the pre-specified second IA of OS with updates of IDFS, DDFS, and safety. Patients and methods: One thousand eight hundred and thirty-six patients were randomly assigned to olaparib or placebo following (neo)adjuvant chemotherapy, surgery, and radiation therapy if indicated. Endocrine therapy was given concurrently with study medication for hormone receptor-positive cancers. Statistical significance for OS at this IA required P < 0.015. Results: With a median follow-up of 3.5 years, the second IA of OS demonstrated significant improvement in the olaparib group relative to the placebo group [hazard ratio 0.68; 98.5% confidence interval (CI) 0.47-0.97; P = 0.009]. Four-year OS was 89.8% in the olaparib group and 86.4% in the placebo group (Δ 3.4%, 95% CI −0.1% to 6.8%). Four-year IDFS for the olaparib group versus placebo group was 82.7% versus 75.4% (Δ 7.3%, 95% CI 3.0% to 11.5%) and 4-year DDFS was 86.5% versus 79.1% (Δ 7.4%, 95% CI 3.6% to 11.3%), respectively. Subset analyses for OS, IDFS, and DDFS demonstrated benefit across major subgroups. No new safety signals were identified including no new cases of acute myeloid leukemia or myelodysplastic syndrome. Conclusion: With 3.5 years of median follow-up, OlympiA demonstrates statistically significant improvement in OS with adjuvant olaparib compared with placebo for gBRCA1/2pv-associated EBC and maintained improvements in the previously reported, statistically significant endpoints of IDFS and DDFS with no new safety signals.
Tipologia CRIS:
Articolo su rivista
Keywords:
adjuvant therapy; BRCA1/2; breast cancer; olaparib; PARP inhibition
Elenco autori:
Geyer, C. E.; Garber, J. E.; Gelber, R. D.; Yothers, G.; Taboada, M.; Ross, L.; Rastogi, P.; Cui, K.; Arahmani, A.; Aktan, G.; Armstrong, A. C.; Arnedos, M.; Balmana, J.; Bergh, J.; Bliss, J.; Delaloge, S.; Domchek, S. M.; Eisen, A.; Elsafy, F.; Fein, L. E.; Fielding, A.; Ford, J. M.; Friedman, S.; Gelmon, K. A.; Gianni, L.; Gnant, M.; Hollingsworth, S. J.; Im, S. -A.; Jager, A.; Johannsson, O. Th.; Lakhani, S. R.; Janni, W.; Linderholm, B.; Liu, T. -W.; Loman, N.; Korde, L.; Loibl, S.; Lucas, P. C.; Marme, F.; Martinez De Duenas, E.; Mcconnell, R.; Phillips, K. -A.; Piccart, M.; Rossi, G.; Schmutzler, R.; Senkus, E.; Shao, Z.; Sharma, P.; Singer, C. F.; Spanic, T.; Stickeler, E.; Toi, M.; Traina, T. A.; Viale, G.; Zoppoli, G.; Park, Y. H.; Yerushalmi, R.; Yang, H.; Pang, D.; Jung, K. H.; Mailliez, A.; Fan, Z.; Tennevet, I.; Zhang, J.; Nagy, T.; Sonke, G. S.; Sun, Q.; Parton, M.; Colleoni, M. A.; Schmidt, M.; Brufsky, A. M.; Razaq, W.; Kaufman, B.; Cameron, D.; Campbell, C.; Tutt, A. N. J.; Sevelda, P.; Haslbauer, F.; Penzinger, M.; Ohler, L.; Tinchon, C.; Greil, R.; Heibl, S.; Bartsch, R.; Wette, V.; Singer, C. F.; Pasterk, C.; Helfgott, R.; Pristauz-Telsnigg, G.; Stoger, H.; Weltermann, A.; Egle, D.; Thiel, I.; Fuchs, D.; Rumpold, H.; Strasser-Weippl, K.; Rautenberg, B.; Muller, V.; Schmidt, M.; Paepke, S.; Aydogdu, M.; Thomssen, C.; Rom, J.; Mau, C.; Fasching, P.; Gohring, U. -J.; Kuhn, T.; Noeding, S.; Kummel, S.; Hackmann, J.; Stickeler, E.; Joshi, A.; Dewar, J.; Friedlander, M.; Antill, Y.; Woodward, N.; Abdi, E.; Tiley, S.; George, M.; Boadle, D.; Goodwin, A.; Van Der Westhuizen, A.; Kannourakis, G.; Murray, N.; Mccarthy, N.; Kroep, J.; De Boer, M.; Heijns, J.; Erdkamp, F.; Bakker, S.; Sonke, G. S.; Sami, A.; Mackey, J.; Prady, C.; Eisen, A.; Desbiens, C.; Patocskai, E.; Ferrario, C.; Bordeleau, L.; Chalchal, H.; Niraula, S.; Ido, Wolf; Duhoux, F.; Randal, D'Hondt; Luce, S.; Roodenbeke, D. T. D.; Papadimitriou, K.; Borms, M.; Quaghebeur, C.; Jacot, W.; Brain, E.; Venat-Bouvet, L.; Lortholary, A.; Nowecki, Z.; Cardoso, F.; Hayward, R.; Bella, S.; Lazzaro, M. F.; Pilnik, N.; Fein, L. E.; Blajman, C.; Lerzo, G.; Varela, M.; Zarba, J. J.; Kaen, D.; Constanzo, M. V.; Tio, J.; Siggelkow, W.; Jackisch, C.; Grischke, E. M.; Zahm, D.; Tato-Varela, S.; Schmatloch, S.; Klare, P.; Stefek, A.; Rhiem, K.; Hoffmann, O.; Deryal, M.; Groll, I.; Ledwon, P.; Uleer, C.; Krabisch, P.; Potenberg, J.; Darsow, M.; Park-Simon, T. -W.; Hoffkes, H. -G.; Emde, T. -O.; Graffunder, G.; Tome, O.; Forstmeyer, D.; Terhaag, J.; Salat, C.; Kast, K.; Weniger, S.; Schreiber, C.; Heinrich, B.; Dieterich, M.; Wullner, M. P.; Conejero, R. A.; Garcia Saenz, J. A.; Martinez, L. C.; Lanza, A. A.; Murillo, S. M.; Carrasco, F. H.; Tormo, S. B.; Lopez, I. A.; Delgado Mingorance, J. I.; Gomez, E. A.; Santisteban, M.; Jurado, J. C.; Quiroga, V.; Borrego, M. R.; Martinez De Duenas, E.; Ales Martinez, J. E.; De La Haba, J.; Janez, N. M.; Lescure, A. R.; Torres, A. A.; Crusades, G. L.; Gonzalez-Santiago, S.; Aragones, A. M.; Ortega, A. L.; Molins, A. B.; Chacon Lopez-Muniz, J. I.; Jimenez, M. M.; Bertran, A. S.; Rodriguez, C.; Cortijo, L. G.; Cretella, E.; Cortesi, L.; Ruggeri, E. M.; Verusio, C.; Gori, S.; Bonetti, A.; Mosconi, A. M.; Johannsson, O.; Jerusalem, G.; Neven, P.; Nagy, T.; Pinotti, G.; Colleoni, M. A.; Bernardo, A.; Gianni, L.; Bucci, E.; Biganzoli, L.; Dedes, K.; Novak, U.; Zaman, K.; Braybrooke, J.; Winter, M.; Rea, D.; Kelleher, M.; Barrett, S.; Chan, S.; Hickish, T.; Hurwitz, J.; Conibear, J.; Jegannathen, A.; Parton, M.; Tutt, A.; Allerton, R.; Borley, A.; Armstrong, A.; Copson, E.; Levitt, N.; Abraham, J.; Perren, T.; Roylance, R.; Ishida, K.; Toyama, T.; Masuda, N.; Watanabe, J.; Tokunaga, E.; Kinoshita, T.; Rai, Y.; Takada, M.; Yanagita, Y.; Nakamura, R.; Nakayama, T.; Naoi, Y.; Iwata, H.; Nakamura, S.; Takahashi, M.; Aogi, K.; Tsugawa, K.; Mukai, H.; Takano, T.; Osaki, A.; Sato, N.; Yamauchi, H.; Tokuda, Y.; Ito, M.; Sugimoto, T.; Bahadur, S. W.;
Autori di Ateneo:
CORTESI LAURA
Link alla scheda completa:
https://iris.unimore.it/handle/11380/1404048
Link al Full Text:
https://iris.unimore.it//retrieve/handle/11380/1404048/974162/ao2022.pdf
Pubblicato in:
ANNALS OF ONCOLOGY
Journal
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.0.0